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Introduction: We analyzed the epidemiology and outcomes of treatment of invasive fungal 
disease (IFD) in children during anticancer therapy (PHO, pediatric hematology and 
oncology) or after hematopoietic cell transplantation (HCT) over a period of eight consecutive 
years in a single-center study. 
Material and methods: Overall, a total of 254 HCTs were performed, and 415 children were 
newly diagnosed for malignancy. Incidence, epidemiology and outcome of IFD were 
analyzed. 
Results: The cumulative incidence of any IFD was 32.6% in allo-HCT, 22.2% in PHO, and 
6.0% in auto-HCT patients. The incidence of proven +probable IFD was 12.6%, 10.4%, and 
6.0%, respectively. As many as 77.0% HCT and 67.4% PHO of fungal episodes occurred in 
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acute leukemia patients: the highest incidence of any IFD was observed for acute 
lymphoblastic leukemia (29.3% in HCT; 40.5% in PHO) and for acute myeloblastic leukemia 
(51.1% in HCT; 65.0% in PHO) patients. There were no significant differences in the 
incidence of fungal infections in both allo-HCT and PHO patients between the 2-year periods. 
Factors contributing to an increased risk of IFD in allo-HCT patients were: CMV replication, 
and acute and chronic graft-versus-host disease (GvHD). Survival from IFD was 91.9% in 
PHO, and 78.1% in HCT patients. Fungal pneumonia in HCT patients resolved in 62.9%, 
while in PHO patients it resolved in 93.5%. 
Conclusions: The risk of IFD in allo-HCT patients is much higher than in auto-HSCT and 
PHO patients. The outcome of IFD is better in PHO and auto-HCT than in allo-HCT settings. 
Key words: fungal infections, malignant diseases, pediatric hematology and oncology, 





Infections constitute a major problem in patients undergoing oncological treatment or 
hematopoietic cell transplantation (HCT) [1–4]. These complications can compromise the 
benefit of both anticancer therapy and transplantation. Oncological wards and transplant units 
are usually equipped with specific programs or guidelines for diagnostics, as well as for 
prophylactic, empirical, pre-emptive and targeted therapeutic management against bacteria, 
viruses, fungi and parasites [5–9]. To date, no strategy has proved entirely successful, and 
thus each center should be aware of its local infectious epidemiology. 
In 2012, a nationwide program on infections in Polish pediatric hematology oncology 
(PHO) and transplant centers was initiated (acronym: iPhot) [10]. This program enabled 
assessment of the incidence and outcome of infections in PHO and pediatric HCT centers in 
various aspects [10–12], including differential analysis with the adult HCT population [13]. 
Results of multicenter analyzes based on the data from 2012–2017 have shown that the worst 
outcome was observed in cases of fungal infections, especially invasive fungal disease (IFD) 
in a transplant setting, both in children and adults [10, 13, 14]. These findings justify a 
focused approach to antifungal management based on the use of antifungal prophylaxis in 
subgroups of patients with the highest incidence of IFD, e.g. in patients undergoing allogeneic 
HCT (allo-HCT) or chemotherapy for acute leukemia. 
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In this context, we analyzed the epidemiology and outcome of treatment of IFD in a 
single-center pediatric study, updated for another two years.  
Thus, the objective of this study was analysis of the incidence and outcome of fungal 
infections in children during anticancer therapy (PHO, pediatric hematology and oncology) or 
after HCT over a period of eight consecutive years in a single-center pediatric study. 
 
 
Material and methods 
Patients 
All children newly diagnosed for malignancy or undergoing HCT during 96 consecutive 
months between 2012 and 2019 were included in the study: 415 patients with newly-




Eight years of epidemiology and outcomes of IFD were analyzed. Data was collected on the 
basis of consecutive 2-year periods determined by the introduction of a national program of 
antifungal prophylaxis with the second generation of azoles: i.e. before prophylaxis (2012–
2013), a transitional period (2014–2015), a period with modern prophylaxis (2016–2017), and 
a continuation period. In 2012–2013 the study was retrospective, and from 2014 it was 
prospective. 
 
Oncological treatment in acute leukemia 
During the analyzed eight-year period, all patients with acute lymphoblastic leukemia (ALL) 
were treated with the Intercontinental Cooperative ALL-IC-2009 protocol up to 30 September 
2018, and subsequently with the AIEOP-BFM-2017 protocol. Patients with acute myeloid 
leukemia (AML) were treated according to the Berlin-Frankfurt-Munster AML-BFM-2004 
protocol up to 2014, and subsequently with the AML-BFM-2012 protocol. 
 
Diagnosis of fungal infections 
Diagnoses of IFD were made, according to the EORTC/MSG criteria, as proven, probable, or 
possible [15, 16]. All HCT and PHO patients were screened with a galactomannan test mainly 
during neutropenia, or on the basis of clinically-driven indications. Computed tomography 
(CT), including high-resolution CT (HRCT) or magnetic resonance imaging (MRI) of an area 
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involved in infection, was performed also on the basis of clinical indications [17]. In cases of 
a new episode of fever, microbiological specimens were used for culture. Biopsy of involved 
tissue was made where this was possible and clinically justified [17, 18]. 
 
Anti-fungal management and supportive therapy 
Standard uniform anti-infective prophylaxis, including an environmental prophylactic 
strategy, was applied to patients undergoing HCT [19–21]. Empirical, preemptive or targeted 
anti-fungal therapy was administered with various antifungal agents according to the current 
commonly accepted strategies [9, 17]. Antifungal prophylaxis was used routinely in allo-HCT 
patients during the neutropenic phase or immunosuppressive therapy, and usually included 
fluconazole or other azoles up to 2014. Subsequently, posaconazole or voriconazole was used 
in allo-HCT patients in cases of graft-versus-host disease (GvHD), and in patients with AML 
or high-risk ALL during conventional chemotherapy, as well as for secondary prophylaxis. In 
patients with ALL, prophylaxis with azoles was rarely used during the induction phase due to 
the potential risk of interaction with vincristine, leading to neurotoxicity and other adverse 
events. During the intensification/consolidation phase, antifungal prophylaxis was used 
between cycles of chemotherapy, while usually being temporarily withdrawn during 
chemotherapy with the use of non-azole antifungal in selected patients. Commercial 
intravenous immunoglobulins were administered monthly in cases of decreased serum 
immunoglobulin concentration after transplantation or oncological therapy until B-cell 
function recovery. 
Antibacterial antibiotic prophylaxis was used in all HCT patients during neutropenia 
or immunosuppressive therapy, and included penicillin or cephalosporin or ciprofloxacine. 
Preemptive or targeted anti-viral therapy was applied according to commonly accepted 
strategies.  
 
Infection-related mortality (IRM) 
Treatment-related mortality (TRM) was defined as any death occurring at any point after the 
start of treatment that did not occur as a result of relapse or secondary malignancy. Outcome 
of infection was regarded as positive in cases of survival from infection or negative in cases 
of death occurring with an infectious complication. For the purpose of this study, IRM 
analysis was restricted to fungal infections, being defined as any death occurring in the 
presence of IFD, starting from the day of diagnosis of the infection. In cases of relapse or 
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progression of malignancy, this event was regarded as the primary cause of death, regardless 
of any diagnosis of concomitant infection. 
 
Ethics 
The authors confirm that the ethical policies of the journal, as noted on the journal’s author 
guidelines page, have been adhered to, and that appropriate ethical review committee 
approval has been received. 
 
Statistical analysis 
Cumulative incidences of fungal infections were calculated using competing risk analysis, 
starting from the day of transplant in an HCT setting, or the day of cancer diagnosis in a PHO 
setting, to the day of the first infection. Death was considered as the competing event. For the 
purpose of cumulative incidence analysis, an event was defined as the diagnosis of a first 
specific infectious disorder. Non-categorical variables were compared with a Mann-Whitney 
U test, and categorical variables were compared with a chi-square test. Hazard risk (HR) and 
95% confidence intervals (95% CI) were calculated for the difference in occurrence of 
infections in patients. The Kaplan-Meier method was used to determine survival from 
invasive fungal infection. 
Multivariate models for the development of fungal infections were calculated using the 
logistic regression model. Variables analyzed in HCT patients included: age (≤10 years, >10 
years); sex (female, male); donor source (matched sibling donor, MSD; mis/matched 
unrelated donor, MUD/MMUD); disease (acute leukemia, other); conditioning intensity 
(myeloablative, other); donor/recipient CMV serostatus (negative/negative, any positive); 
CMV replication (absent/present); acute GvHD occurring before infection onset (grade 0/1, 
grade 2–4); and chronic GvHD occurring before infection onset (no, yes). Use of ATG (anti-
thymocyte globulin) was a variable dependent on alternative donor, as it was used almost 
exclusively in MUD/MMUD transplants. The stepwise selection procedure was used to select 





Over the analyzed period of 96 consecutive months, a total of 415 PHO patients were newly 
diagnosed for malignancy, including 121 with acute lymphoblastic leukemia (ALL), 20 with 
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acute myeloblastic leukemia (AML), 35 with non-Hodgkin’s lymphoma (NHL), 39 with 
Hodgkin’s Disease (HD), 61 with central nervous system tumors (CNS), 20 with 
neuroblastoma (NBL), 17 with Wilms tumor (WT), 13 with Ewing sarcoma (ES), six with 
osteosarcoma (OST), 25 with rhabdomyosarcoma (RMS), 13 with germ cell tumors (GCT), 
and 25 with other solid tumors (ST). During this period, a total of 254 HCTs were performed 
including 187 allo-HCTs and 67 auto-HCTs. Children were transplanted due to ALL (n =82), 
AML (n =45), NHL/HD (n =19), MDS (n =10), bone marrow failure syndromes (BMF, n 
=25), primary immunodeficiency (PID, n =15), neuroblastoma (NBL, n =32), Ewing sarcoma 
(n =13), or other diseases (n =13) (Table I).  
 
Incidence of infections 
The cumulative incidence of fungal infections between 2012 and 2019 in PHO patients was 
22.2% (95% CI =18.2–26.2), while in HCT patients it was 25.3% (95% CI =20.0–30.6) (p 
=0.214) (Figure 1). The overall risk of any IFD in HCT (allo +auto) vs. PHO patients was 
similar: HR =1.2 (95% CI =0.8–1.7; p =0.357). Also, the risk of proven +probable IFD for 
HCT (allo +auto) vs. PHO was similar: HR =1.1 (95% CI =0.6–1.8; p =0.897). With respect 
to the type of transplant, the cumulative incidence of fungal infections was much higher after 
allo-HCT than after auto-HCT: 32.6% vs. 6.0% (HR =7.6, 95% CI =2.6–22.0; p <0.0001). 
There were no significant differences in the incidence of fungal infections both in allo-
HCT and PHO patients between the 2-year periods. Respective values for subsequent two-
year periods for PHO vs. HCT were: 14.8% vs. 24.2% for 2012–2013 (p =0.092), 24.2% vs. 
22.0% for 2014–2015 (p =0.8), 25.0% vs. 28.8% for 2016–2017 (p =0.4), and 25.7% vs. 
26.0% for 2018–2019 (p =0.8). 
The majority of fungal infections occurred within the first four months, and earlier 
after allo-HCT than in PHO patients after diagnosis of the malignancy. The median time to 
first fungal infection was shorter after allo-HCT than in PHO patients after diagnosis of 
malignancy: 2.2 months vs. 3.5 months, p <0.001. Due to sporadic infections after auto-HCT, 
a respective comparison was not carried out. 
The overall risk of any IFD in allo-HCT vs. PHO patients was significantly higher up 
to day 100 (from transplant or cancer diagnosis, respectively): HR =2.3 (95% CI =1.5–3.5; p 
<0.001), and then lower after day 100: HR =0.5 (95% CI =0.3–1.0; p =0.073). The overall 
risk of proven +probable IFD in allo-HCT vs. PHO patients was significantly higher up to day 
100 (from transplant or cancer diagnosis, respectively): HR =2.5 (95% CI =1.3–4.7; p 
=0.006), and then lower after day 100: HR =0.4 (95% CI =0.1–1.1; p =0.098). 
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The cumulative incidence of IFD among PHO patients was 22.2%, including proven 
IFD in 5.3%, probable in 5.1%, and possible in 11.8% of patients (Figure 2). As many as 
67.4% of IFD episodes occurred in acute leukemia patients. IFD incidence was 40.5% among 
ALL patients (proven 8.3%, probable 10.7%, possible 22.3%), and 65.0% among AML 
patients (proven 15.0%, probable 5.0%, possible 45.0%). In other types of cancer, the 
incidence of IFD was: NHL 25.7%, RMS 12.0%, CNS 9.8%, NBL 20.0%, ES 7.7%, GCT 
7.7%, WT 0%, osteosarcoma 0%, and other solid tumors 20.0%. 
IFD incidence among allo-HCT patients was 32.6%, including proven in 4.9%, 
probable in 7.7%, and possible IFD in 17.5% patients (Figure 1). Altogether, 77% of the IFD 
cases were reported in acute leukemia patients. IFD incidence was 29.3% among ALL 
(proven 4.9%, probable 7.3%, possible 17.1%), and 51.1% among AML patients (proven 
2.2%, probable 13.3%, possible 35.6%). The incidence of IFD was 36.0% in BMF, 30.0% in 
MDS, and 13.3% in PID. Additionally, the incidence of IFD in auto-HCT was 6.3% in NBL, 
11.1% in NHL, and 10% in HD. 
The number of infections with respect to time periods is shown in Table II. Proven 
IFDs were diagnosed in 22 PHO and 13 HCT patients, with 25 and 13 identified fungal 
species, respectively (Table III). Candida spp. was the most prevalent causative factor, 
detected mainly as a blood-stream infection. 
 
Risk factors of infections in allo-HCT patients 
Factors contributing to an increased risk of fungal infections both in uni- and multivariate 
analysis were: CMV replication, and acute and chronic GvHD (Table IV). Fungal infections 
were also less likely after non-myeloablative or reduced-intensity conditioning, although this 
did not reach statistical significance. 
 
Survival after fungal infections 
Survival from IFD was 91.9% in PHO, and 78.1% in HCT patients. With respect to IFD level 
of diagnosis in PHO, patients with possible IFD had a 98.6% cure rate, while probable and 
proven IFD had comparable cure rates of 84–85% (Figure 2). In HCT patients, no significant 
differences were found in the cure rate, although possible IFD resolved in 72.1%, probable in 
78.0%, and proven in 90.5%. Fungal pneumonia in HCT patients resolved only in 62.9% vs. 
100% in extrapulmonary involvement (p =0.016), while in PHO patients there were no 
differences: 93.5% vs. 88.4% (p =0.3). Antifungal monotherapy was related to a higher cure 
rate than combined antifungal treatment, both in PHO patients (96.0% vs. 80.0%, p =0.003), 
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and HCT patients (84.1% vs. 66.7%, p =0.057). However, it should be noted that combined 




This long-term study of the incidence and outcome of fungal infections in children during 
anticancer therapy (PHO) or after undergoing HCT in a single-center analysis has shown 
comparably high incidences of both any and proven +probable IFD in allo-HCT and PHO 
patients, and much lower incidence in auto-HCT. 
In other studies, infections occur in overall 82% of children after allo-HCT [22], 21% 
after auto-HCT, and 49% with acute leukemia in a PHO setting [23]. With respect to HCT 
recipients, infections accounted for 13% of deaths after matched sibling donor HCT, 17% 
after unrelated donor HCT, and 7% after auto-HCT [24]. IFD was diagnosed in 12% of 
children within the first 30 days after allo-HCT [22], and was rare after auto-HCT [23]. In 
general, 53% all allo-HCT infectious deaths were caused by fungi, 20% by bacteria, 24% by 
viruses, and 3% by parasites [22], while deaths due to infections were rare after auto-HCT 
[23]. In analysis of autopsies, infections have been found to be the cause of death in 55% of 
adults after allo-HCT, and in 18% after auto-HCT [25]. Overall, IFD, cytomegalovirus 
(CMV) and bacteria are the main non-relapse risk factors for deaths after HCT [26, 27]. 
In this context, our analysis has shown a higher incidence of any IFD both in PHO and 
allo-HCT settings. However, when proven or probable IFDs are taken into account, the 
incidences are comparable to other international pediatric data. It remains unclear which is the 
real threat of IFD diagnosed on a ‘possible’ level, something which is being diagnosed in over 
50% of IFD cases, both in PHO and allo-HCT settings. Surprisingly, the outcome of possible 
IFD, although non-significantly, was lower than probable or proven IFD in HCT patients. 
This was not the case in PHO patients. The proven worse outcomes of possible IFDs lead to 
the issue of diagnosis at the level of biomarkers, imaging and tissue biopsy.  
Given that in the majority of cases the possible IFD was diagnosed in patients with 
pneumonia, based on clinical signs and symptoms, and computed tomography imaging, it 
must be underscored that invasive diagnostics in a pediatric population in such cases is very 
difficult. Neither bronchoscopy with broncho-alveolar lavage (BAL), nor lung biopsy, is a 
standard procedure yet in children after allo-HCT, although both these diagnostic techniques 
are being performed more frequently nowadays. 
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Another surprising outcome of our study is the better survival after antifungal 
monotherapy than after combined therapy. In general, it has been proven that combination 
therapy is more successful than monotherapy in first-line therapy of IFD [28]. In our study, 
however, combination therapy was applied almost exclusively as the second-line treatment 
after a lack of improvement in first-line therapy. This aligns with national [17] and 
international recommendations [9]. 
Our study highlights the negative role of CMV replication as an adverse factor leading 
to increased incidence of IFD. This indirect effect of viral infection is also a risk factor of 
mortality after HCT [29, 30]. 
Antifungal prophylaxis introduced in HCT patients and in patients with acute 
leukemias in 2014–2015, slowed down the increase in incidence of fungal infections from 
2016 onwards, although it did not stop it. Looking into possible activities, other options to 
improve the outcome of IFD might be: wider use of invasive diagnostics, treatment with 
reference antifungals according to recommendations [9, 17], use of minimally-invasive 
surgery in diagnostics and treatment [31, 32], or successful prophylaxis and treatment of viral 
infections preceding development of IFD [4, 33, 34]. New diagnostic methods and antifungals 
may appear. 
The strengths of our study are the collection of all necessary clinical data, as well as 
uniform diagnosis and treatment of patients. The same factors also serve as limitations of our 
study, because a single-center study carries the bias of a specific approach and similar 
interventions performed in the majority of patients. 
In conclusion, the risk of IFD in allo-HCT patients is much higher than in auto-HSCT 
and PHO patients. Most fungal episodes occurred in acute leukemia patients, in both the allo-
HCT and PHO groups. As expected, the outcome of IFD was better in the PHO and auto-HCT 
setting than in the allo-HCT setting. Fungal infection-related mortality was highest in 
transplant patients with pneumonia. 
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Figure 1. Cumulative incidence of IFD: (A) in PHO vs. HCT; (B) in PHO vs. allo-HCT vs. 
auto-HCT; (C) in PHO with respect to level of IFD diagnosis; (D) in HCT with respect to 



















Figure 2. Survival from IFD: (A) in PHO vs. HCT; (B) in PHO with respect to level of 
diagnosis; (C) in HCT with respect to level of IFD diagnosis; (D) in HCT patients in 
pulmonary vs. extrapulmonary IFD; (E) in PHO with respect to antifungal monotherapy vs. 








Table I. Primary diseases of analyzed patients 
Variable HCT PHO 




Acute myeloblastic leukemia 45 20 
Non-Hodgkin’s lymphoma 9 35 
Hodgkin’s Disease 10 39 
Solid tumors 58 (32 NBL, 13 ES, 13 
other) 
180 (61 CNS, 20 NBL, 17 
WT, 13 ES, 6 OST, 25 RMS, 
13 GCT, 25 other) 
Other 15 PID, 25 BMF, 10 MDS 13 LCH, 2 CML, 2 MDS 
*NBL – neuroblastoma; ES — Ewing sarcoma; PID — primary immunodeficiency; BMF — 
bone marrow failure syndrome; MDS — myelodysplastic syndrome; CNS — central nervous 




GCT — germ cell tumor; LCH — Langerhans cell histiocytosis; CML — chronic myeloid 




Table II. Hazard risk of infections after HCT compared to PHO patients with respect to time 
periods 






























































    


















































95% CI  
=0.6–1.8 
HR =0.2 
95% CI  
=0.05–
HR =0.7 
95% CI  
=0.3–2.0 
HR =9.0 




Total IFD p =0.008 p <0.001 p =0.999 0.97 
p =0.053 





























HR — hazard risk; CI — confidence interval; p — p-value; N/A — not applicable; HCT — 
hematopoietic cell transplantation; PHO — pediatric hematology and oncology 
 
 
Table III. Etiology of proven fungal infections 
Infection PHO 
(25 species in 22 
patients) 
HCT 
















































*Denotes fluconazole-sensitive strains of non-albicans Candida; PHO — pediatric 





Table IV. Risk factor analysis for fungal infections in allo-HCT patients 
Variable Characteristi
cs 
Univariate analysis Multivariate analysis 













































































GvHD — graft-versus-host-disease; MFD — matched family donor; RR — relative risk 
